Study of Experience of High-frequency Repetitive Transcranial

Status Completed

Clinical Trial Summary

Objective: To understand the personal experience of schizophrenia patients following repetitive transcranial magnetic stimulation (rTMS) and its connection with changes in mental symptoms, thereby enhancing the overall understanding of TMS. Method: The investigators selected eligible schizophrenia patients for fixed-parameter rTMS treatment. A self-experience checklist post-TMS treatment and positive and negative symptom scales (PANSS) were applied to evaluate the treatment.

Clinical Trial Description

The investigators recruited male subjects admitted to who met the criteria. They were divided into a control and a treatment group. A double-blind approach was adopted. The subjects were unaware of whether real/pseudo stimulation was applied, and the evaluators did not know the grouping specifics. All of the enrolled cases were tested for stimulation thresholds in the bilateral prefrontal cortex. The TMS treatment device was a Magstim RAPID2 neuromagnetic stimulator (Magstim) with an "8"-type coil. The study group was administered real stimulation. The treatment parameters were as follows: frequency range, 20 Hz; 90% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times. For the control group, a 60% motion threshold was set; the remaining parameters were consistent with the study group but with no stimulating energy output. The therapeutic instrument model, appearance, operation process, and sounds when effecting treatment were the same for both groups. A self-experience checklist post-TMS treatment and positive and negative symptom scales (PANSS) were applied to evaluate the treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05809882
Study type	Interventional
Source	Rongjun Hospital of Hebei Province Affiliated to North China University of Science and Technology
Contact
Status	Completed
Phase	N/A
Start date	March 1, 2019
Completion date	February 20, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00161044` - An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms	N/A
Completed	`NCT01450514` - POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia	Phase 2
Recruiting	`NCT05948696` - Experience of Horticultural Group Therapy Among People With Chronic Schizophrenia
Completed	`NCT06206798` - Resourcefulness Group Intervention on Recovery and Quality of Life	N/A
Completed	`NCT01761383` - Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic Schizophrenia	N/A
Completed	`NCT01891929` - Cognitive Remediation and Sheltered Employment in Schizophrenia	N/A
Completed	`NCT03275909` - Integrated Psychological Therapy for Chronic Schizophrenia	N/A
Completed	`NCT02298985` - Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients	Phase 4
Recruiting	`NCT00525863` - Oxygen Therapy in Schizophrenia	Phase 3
Completed	`NCT02624167` - A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia	Phase 2
Completed	`NCT00789698` - Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia	Phase 3
Recruiting	`NCT06349369` - Effect of tDCS on Inflammatory Biomarkers in Chronic Schizophrenia	N/A
Completed	`NCT02421146` - The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study	N/A
Active, not recruiting	`NCT00664274` - Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia	N/A
Terminated	`NCT00148616` - Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia	Phase 3